ABL Diagnostics, a Euronext-listed company that develops molecular biology assays and software for microbiology laboratories, has announced a major evolution of its research & development activities with the design of CRISPRChek, a new line of molecular assays using the disruptive CRISPR technology. The company is investing in a technology with the potential to achieve ultra-high sensitivity…